Methods for treating MS by inhibiting astrocyte proliferation in the brain with interferon 2-beta, thereby reducing inflammation

Described are nucleic acids and polypeptide sequences that code for an interferon-beta-2 ("IFN-beta2"). A pharmaceutical composition, which comprises a pharmaceutically acceptable excipient and a therapeutically effective amount of a human IFN-beta2 polypeptide, biologically active fragmen...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	CROZE, EDWARD M, WAGNER, CHARIS T, FAULDS, DARYL
Format:	Patent
Sprache:	eng
Schlagworte:	CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page
container_issue
container_start_page
container_title
container_volume
creator	CROZE, EDWARD M WAGNER, CHARIS T FAULDS, DARYL
description	Described are nucleic acids and polypeptide sequences that code for an interferon-beta-2 ("IFN-beta2"). A pharmaceutical composition, which comprises a pharmaceutically acceptable excipient and a therapeutically effective amount of a human IFN-beta2 polypeptide, biologically active fragment thereof, or biologically-active derivative thereof, is useful in treating multiple sclerosis in humans. The graph depicts the antiviral activity of IFN-beta2 and IFN-beta1b. Human WISH cells were stimulated with either IFN-beta1b or IFN-beta2 followed by infection with vesicular stomatitis virus (VSV). Viral cytopathic effect (CPE) was measured using the redox dye Alamar Blue. Units of antiviral activity corresponding to IFN-beta1b are plotted along the X-axis. Specific antiviral activity of IFN-beta2 was determined to be 4.0-8.0 x106 International Units ("IU") per mg. Using this assay, IFN-beta2 demonstrates functional properties similar to those of IFN-beta1b.
format	Patent
fullrecord	<record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_NZ522849A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>NZ522849A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_NZ522849A3</originalsourceid><addsrcrecordid>eNqFjLEKwkAQRNNYiPoLsh9gmqigpYhiExutbMJesucdXO7C3oqk89O9BHurGWYeb5p9ShITmgg6MAgTivVPKG-gerDeWGXHAaNwqHsh6Dg4q4kTGHxCQAyBYkztbcWkRYjTn84iVyS4Ggim5GNqXvVgs147bNtRMc8mGl2kxS9n2fJ8uh8vOXWhothhTZ6kuj62RbHb7A_rv8AXmkNIZg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Methods for treating MS by inhibiting astrocyte proliferation in the brain with interferon 2-beta, thereby reducing inflammation</title><source>esp@cenet</source><creator>CROZE, EDWARD M ; WAGNER, CHARIS T ; FAULDS, DARYL</creator><creatorcontrib>CROZE, EDWARD M ; WAGNER, CHARIS T ; FAULDS, DARYL</creatorcontrib><description>Described are nucleic acids and polypeptide sequences that code for an interferon-beta-2 ("IFN-beta2"). A pharmaceutical composition, which comprises a pharmaceutically acceptable excipient and a therapeutically effective amount of a human IFN-beta2 polypeptide, biologically active fragment thereof, or biologically-active derivative thereof, is useful in treating multiple sclerosis in humans. The graph depicts the antiviral activity of IFN-beta2 and IFN-beta1b. Human WISH cells were stimulated with either IFN-beta1b or IFN-beta2 followed by infection with vesicular stomatitis virus (VSV). Viral cytopathic effect (CPE) was measured using the redox dye Alamar Blue. Units of antiviral activity corresponding to IFN-beta1b are plotted along the X-axis. Specific antiviral activity of IFN-beta2 was determined to be 4.0-8.0 x106 International Units ("IU") per mg. Using this assay, IFN-beta2 demonstrates functional properties similar to those of IFN-beta1b.</description><edition>7</edition><language>eng</language><subject>CHEMISTRY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2004</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20040528&DB=EPODOC&CC=NZ&NR=522849A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76290</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20040528&DB=EPODOC&CC=NZ&NR=522849A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>CROZE, EDWARD M</creatorcontrib><creatorcontrib>WAGNER, CHARIS T</creatorcontrib><creatorcontrib>FAULDS, DARYL</creatorcontrib><title>Methods for treating MS by inhibiting astrocyte proliferation in the brain with interferon 2-beta, thereby reducing inflammation</title><description>Described are nucleic acids and polypeptide sequences that code for an interferon-beta-2 ("IFN-beta2"). A pharmaceutical composition, which comprises a pharmaceutically acceptable excipient and a therapeutically effective amount of a human IFN-beta2 polypeptide, biologically active fragment thereof, or biologically-active derivative thereof, is useful in treating multiple sclerosis in humans. The graph depicts the antiviral activity of IFN-beta2 and IFN-beta1b. Human WISH cells were stimulated with either IFN-beta1b or IFN-beta2 followed by infection with vesicular stomatitis virus (VSV). Viral cytopathic effect (CPE) was measured using the redox dye Alamar Blue. Units of antiviral activity corresponding to IFN-beta1b are plotted along the X-axis. Specific antiviral activity of IFN-beta2 was determined to be 4.0-8.0 x106 International Units ("IU") per mg. Using this assay, IFN-beta2 demonstrates functional properties similar to those of IFN-beta1b.</description><subject>CHEMISTRY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2004</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqFjLEKwkAQRNNYiPoLsh9gmqigpYhiExutbMJesucdXO7C3oqk89O9BHurGWYeb5p9ShITmgg6MAgTivVPKG-gerDeWGXHAaNwqHsh6Dg4q4kTGHxCQAyBYkztbcWkRYjTn84iVyS4Ggim5GNqXvVgs147bNtRMc8mGl2kxS9n2fJ8uh8vOXWhothhTZ6kuj62RbHb7A_rv8AXmkNIZg</recordid><startdate>20040528</startdate><enddate>20040528</enddate><creator>CROZE, EDWARD M</creator><creator>WAGNER, CHARIS T</creator><creator>FAULDS, DARYL</creator><scope>EVB</scope></search><sort><creationdate>20040528</creationdate><title>Methods for treating MS by inhibiting astrocyte proliferation in the brain with interferon 2-beta, thereby reducing inflammation</title><author>CROZE, EDWARD M ; WAGNER, CHARIS T ; FAULDS, DARYL</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_NZ522849A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2004</creationdate><topic>CHEMISTRY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>CROZE, EDWARD M</creatorcontrib><creatorcontrib>WAGNER, CHARIS T</creatorcontrib><creatorcontrib>FAULDS, DARYL</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>CROZE, EDWARD M</au><au>WAGNER, CHARIS T</au><au>FAULDS, DARYL</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Methods for treating MS by inhibiting astrocyte proliferation in the brain with interferon 2-beta, thereby reducing inflammation</title><date>2004-05-28</date><risdate>2004</risdate><abstract>Described are nucleic acids and polypeptide sequences that code for an interferon-beta-2 ("IFN-beta2"). A pharmaceutical composition, which comprises a pharmaceutically acceptable excipient and a therapeutically effective amount of a human IFN-beta2 polypeptide, biologically active fragment thereof, or biologically-active derivative thereof, is useful in treating multiple sclerosis in humans. The graph depicts the antiviral activity of IFN-beta2 and IFN-beta1b. Human WISH cells were stimulated with either IFN-beta1b or IFN-beta2 followed by infection with vesicular stomatitis virus (VSV). Viral cytopathic effect (CPE) was measured using the redox dye Alamar Blue. Units of antiviral activity corresponding to IFN-beta1b are plotted along the X-axis. Specific antiviral activity of IFN-beta2 was determined to be 4.0-8.0 x106 International Units ("IU") per mg. Using this assay, IFN-beta2 demonstrates functional properties similar to those of IFN-beta1b.</abstract><edition>7</edition><oa>free_for_read</oa></addata></record>
fulltext	fulltext_linktorsrc
identifier
ispartof
issn
language	eng
recordid	cdi_epo_espacenet_NZ522849A
source	esp@cenet
subjects	CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
title	Methods for treating MS by inhibiting astrocyte proliferation in the brain with interferon 2-beta, thereby reducing inflammation
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T15%3A02%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=CROZE,%20EDWARD%20M&rft.date=2004-05-28&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ENZ522849A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true